Following promising ASCO readout for AMG 510, Amgen looks to identify more KRAS-mutant patients

After making a strong showing at ASCO with data for its KRAS inhibitor in non-small cell lung cancer patients, Amgen will now look to expand the program's options for finding trial-eligible patients.

Amgen Inc. (NASDAQ:AMGN) reported updated Phase I data on Monday showing that AMG 510 led to five partial responses and four cases of stable disease among 10 evaluable NSCLC patients with KRAS G12C mutations. One patient with a partial response improved further to a complete response of the target lesions at week 18, post the data cutoff. ...